Erysipelothrix rhusiopathiae antibody and antigen (recombinant protein)
Diagnostic anti-Erysipelothrix rhusiopathiae antibodies pairs and antigen for animal health (animal Swine/Porcine/Pig infectious disease erysipelas) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT
Go to Swine/Porcine/Pig disease testing products collection
>>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-VT-P130-Ag01 | Recombinant Erysipelothrix rhusiopathiae protein | $3090.00 |
GMP-VT-P130-Ab01 | Anti-Erysipelothrix rhusiopathiae mouse monoclonal antibody (mAb) | $3090.00 |
GMP-VT-P130-Ab02 | Anti-Erysipelothrix rhusiopathiae mouse monoclonal antibody (mAb) | $3090.00 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. | GMP-VT-P130-Ag01 |
Product Name | Recombinant Erysipelothrix rhusiopathiae protein |
Pathogen | Erysipelothrix rhusiopathiae |
Expression platform | E.coli |
Isotypes | Recombinant Antigen |
Bioactivity validation | Anti-Erysipelothrix rhusiopathiae antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Erysipelothrix rhusiopathiae level test of animal Swine/Porcine/Pig infectious disease with erysipelas. |
Tag | His | Product description | Recombinant Erysipelothrix rhusiopathiae proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-VT-P130-Ab01,GMP-VT-P130-Ab02 |
Pathogen | Erysipelothrix rhusiopathiae |
Product Name | Anti-Erysipelothrix rhusiopathiae mouse monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Recombinant Erysipelothrix rhusiopathiae antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Erysipelothrix rhusiopathiae antibodies in Erysipelothrix rhusiopathiae level test of animal Swine/Porcine/Pig infectious disease with erysipelas. |
Product description | Anti-Erysipelothrix rhusiopathiae mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Erysipelothrix rhusiopathiae antibodies./td> |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Pathogen
Erysipelothrix rhusiopathiae is a bacterial pathogen that infects a wide range of animal species, including humans. This Gram-positive, rod-shaped bacterium belongs to the phylum Firmicutes and is characterized by an array of cell surface proteins that facilitate adhesion to host tissues as well as immune system evasion.
The main gene and protein of Erysipelothrix rhusiopathiae have not been fully elucidated. However, the bacterium produces several virulence factors, including potent exotoxins, lipoteichoic acid, and other surface proteins that enhance its ability to colonize and survive within host tissues.
In pigs, Erysipelothrix rhusiopathiae causes a devastating systemic disease known as erysipelas. The disease is characterized by fever, arthritis, and skin lesions that range from localized redness to widespread and potentially fatal infections. In birds, the bacterium can cause septicemia, while in fish, it can cause "fish erysipelas," a condition that leads to severe hemorrhaging and death.
In humans, Erysipelothrix rhusiopathiae infections are typically associated with occupational exposures, such as meat processing and fish handling. Infection can occur through skin wounds or ingestion of contaminated food. The resulting disease is often marked by localized cellulitis, with symptoms that range from pain, redness, and swelling at the site of infection to more severe manifestations such as septicemia, endocarditis, and arthritis.
Diagnosis of Erysipelothrix rhusiopathiae infections typically involves the isolation and identification of the bacterium from infected tissue samples or blood cultures. PCR-based assays targeting virulence genes like spaA and sodB and serological tests such as ELISA and agglutination assays that detect anti-Erysipelothrix rhusiopathiae antibodies are also commonly used.
Nucleic acid-based methods that target the 16S rRNA gene can also be used for diagnosis. These methods are highly sensitive and can detect low levels of the bacterium in clinical specimens. Moreover, they can be used to identify different strains of Erysipelothrix rhusiopathiae, which is important for epidemiological studies and outbreak investigations.
Treatment of Erysipelothrix rhusiopathiae infections typically involves antibiotics, with penicillin being the drug of choice. Early and prompt treatment is crucial, especially in severe cases of the disease. In addition to antibiotics, supportive care is also important to manage the symptoms of infection.
In conclusion, Erysipelothrix rhusiopathiae is a diverse and adaptable bacterial pathogen that poses significant health risks to both humans and animals. Its ability to colonize and survive within host tissues makes it an effective pathogen, and its persistence in the environment makes it difficult to control. Accurate and timely diagnosis is crucial for effective treatment and control of Erysipelothrix rhusiopathiae infections.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.